| 摘要 |
<p><P>PROBLEM TO BE SOLVED: To provide fully human anti-human IGFR1 monoclonal antibodies which are useful for treating or preventing diseases which are mediated by IGFR1 (e.g., malignancy). <P>SOLUTION: There is provided a binding composition specifically binding to IGFR1, which includes a member selected from the group consisting of a light chain amino acid sequence comprising CDR-L1, CDR-L2, and CDR-L3; and a heavy chain amino acid sequence comprising CDR-H1, CDR-H2, and CDR-H3. A neutralizing human anti-IGFR antibody includes fully human, neutralizing monoclonal antibodies against the human IGFR1. The antibody is useful for treating or preventing cancer in a subject. There also are included methods of using and producing the antibody. <P>COPYRIGHT: (C)2011,JPO&INPIT</p> |
